Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

5 Apr 2018 07:00

RNS Number : 8631J
Advanced Oncotherapy PLC
05 April 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Advanced Oncotherapy plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Peter Gyllenhammar

City and country of registered office (if applicable)

Stockholm, Sweden

4. Full name of shareholder(s) (if different from 3.)v

Name

Peter Gyllenhammar AB

City and country of registered office (if applicable)

Stockholm, Sweden

5. Date on which the threshold was crossed or reachedvi:

04/04/2018

6. Date on which issuer notified (DD/MM/YYYY):

04/04/2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.38%

3.38%

150,501,673

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

5,092,733

3.38%

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Peter Gyllenhammar AB

3.38%

3.38%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Stockholm, Sweden

Date of completion

04/04/2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUSRNRWOASRAR
Date   Source Headline
1st Mar 20227:00 amRNSOperational update
28th Feb 20225:00 pmRNSTotal Voting Rights
17th Feb 20224:25 pmRNSExercise of Warrants and Issue of Equity
31st Jan 20225:00 pmRNSTotal Voting Rights
13th Jan 20223:17 pmRNSExercise of Warrants and Issue of Equity
31st Dec 20211:00 pmRNSTotal Voting Rights
13th Dec 20217:00 amRNSTechnical update on delivery of first LIGHT system
10th Dec 20217:00 amRNSHolding(s) in Company
3rd Dec 20215:09 pmRNSHolding(s) in Company
2nd Dec 20211:29 pmRNSIssue of warrants and equity and Loan Extension
30th Nov 20215:00 pmRNSTotal Voting Rights
15th Nov 20218:30 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): On the home straight
10th Nov 202111:23 amRNSHolding(s) in Company
8th Nov 20212:28 pmRNSExercise of Warrants and Issue of Equity
4th Nov 20211:44 pmRNSHolding(s) in Company
27th Oct 20217:00 amRNSPresentation highlights LIGHT system superiority
30th Sep 20215:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSInterim Results
23rd Sep 202111:27 amRNSExercise of Warrants and Issue of Equity
20th Sep 20217:00 amRNSUpdate re admission of Subscription Shares
3rd Sep 20217:00 amRNSUpdate on admission of Subscription Shares
31st Aug 20216:14 pmRNSResult of GM, TVR and clarification re warrants
16th Aug 20214:48 pmRNSExercise of Warrants and Issue of Equity
12th Aug 20211:50 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO) Funded to completion
11th Aug 20217:00 amRNSProposed subscription and issuance of shares
2nd Aug 20213:37 pmRNSResult of AGM
30th Jul 20214:58 pmRNSResult of AGM
13th Jul 20212:19 pmRNSHoldings in company
30th Jun 20217:00 amRNSFinal Results for the year ended 31 December 2020
3rd Jun 20217:00 amRNSSaba Partners sign LOI for LIGHT system
28th May 20215:00 pmRNSTotal Voting Rights
26th May 202110:37 amRNSExercise of Warrants and Issue of Equity
28th Apr 20215:38 pmRNSExercise of Warrants and Issue of Equity
31st Mar 20215:00 pmRNSTotal Voting Rights
12th Mar 20217:00 amRNSStudy shows the potential superiority of LIGHT
11th Mar 20217:00 amRNSExercise of Warrants and Issue of Equity
26th Feb 20215:00 pmRNSTotal Voting Rights
17th Feb 202110:39 amRNSExercise of Warrants and Issue of Equity
22nd Jan 20217:00 amRNSEquity fundraise of c.£5.9m
13th Jan 20217:00 amRNSExercise of Warrants and Issue of Equity
11th Jan 20217:00 amRNSTechnical update
6th Jan 202111:05 amRNSSecond Price Monitoring Extn
6th Jan 202111:00 amRNSPrice Monitoring Extension
6th Jan 20217:00 amRNSFinancing partnership agreement with DiaMedCare AG
15th Dec 20207:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Leveraging the modularity of LIGHT
23rd Nov 20202:42 pmRNSHolding(s) in Company
17th Nov 20202:02 pmRNSHolding(s) in Company
10th Nov 20207:00 amRNSHolding(s) in Company
30th Oct 20205:00 pmRNSTotal Voting Rights
26th Oct 20207:00 amRNSEquity fundraise of c.£7.7m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.